PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
|Articles|March 15, 2013
Analytical Technology Introductions Planned for Pittcon 2013
Author(s)Pharmaceutical Technology Editors
Scientists and instrument manufacturers gather in Philadelphia for Pittcon 2013.
Advertisement
The
The exposition floor includes 1,926 booths and 18 seminar rooms, hosting 1,011 exhibitors (as of March 1, 2013) displaying products and services used by the scientific community in industrial, academic, and government labs. A mini-museum display of instrumentation, presented by the Chemical Heritage Foundation, celebrates the 100th anniversary of mass spectrometry.
The conference program features workshops, symposia, and short courses on chromatography, molecular and atomic spectroscopy, electrochemistry, mass spectrometry, and lab-on-chip technology.
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement